MaxCyte, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MXCT Nasdaq 2830 www.maxcyte.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MaxCyte, Inc.

VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering - Jun 23rd, 2026 7:00 am
12 Health Care Stocks Moving In Wednesday's Intraday Session - May 13th, 2026 11:06 am
Here’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors - May 13th, 2026 3:27 am
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday - May 13th, 2026 2:14 am
MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ... - May 12th, 2026 11:01 pm
MaxCyte Q1 Earnings Call Highlights - May 12th, 2026 7:09 pm
MaxCyte, Inc. Q1 2026 Earnings Call Summary - May 12th, 2026 6:53 pm
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - May 12th, 2026 3:40 pm
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance - May 12th, 2026 2:05 pm
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026 - Apr 29th, 2026 2:05 pm
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 31st, 2026 2:05 pm
MaxCyte, Inc. Q4 2025 Earnings Call Summary - Mar 25th, 2026 6:30 am
MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ... - Mar 24th, 2026 9:01 pm
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - Mar 24th, 2026 3:49 pm
MaxCyte Q4 Earnings Call Highlights - Mar 24th, 2026 3:41 pm
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates - Mar 24th, 2026 3:35 pm
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance - Mar 24th, 2026 2:05 pm
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer - Mar 23rd, 2026 6:05 am
MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug Discovery - Feb 25th, 2026 3:46 am
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery - Feb 24th, 2026 6:05 am